Navigation Links
Study: Genetic Risk for Substance Use Can be Neutralized by Good Parenting
Date:2/10/2009

A genetic risk factor that increases the likelihood that youth will engage in substance use can be neutralized by high levels of involved and supportive parenting, according to a new University of Georgia study.

Athens, Ga. (PRWEB) February 10, 2009 -- A genetic risk factor that increases the likelihood that youth will engage in substance use can be neutralized by high levels of involved and supportive parenting, according to a new University of Georgia study.

The study, published in the February issue of the Journal of Consulting and Clinical Psychology, is the first to examine a group of youth over time to see how a genetic risk factor interacts with a child's environment to influence behavior.

"We found that involved and supportive parenting can completely override the effects of a genetic risk for substance abuse," says study co-author Gene Brody, Regents Professor in the UGA College of Family and Consumer Sciences. "It's a very encouraging finding that shows the power of parenting."

Brody and his colleagues, who include UGA Institute for Behavioral Research director Steven Beach and University of Iowa Associate Professor of Psychiatry Robert Philibert, focused their attention on a gene known as 5HTT that's involved in the transport of the brain chemical serotonin. Most people carry two copies of the long ve
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Study: Genetic risk for substance use can be neutralized by good parenting
2. Pediatrics study: Involve adolescents in end-of-life medical decisions
3. U-M Study: 19% of Breast Cancer Patients Dont Receive Recommended Radiation After Mastectomy
4. New Study: Protein in the Morning Helps Dieters Stay on Track and Keep Weight Off
5. Twin study: Diabetes significantly increases risk for Alzheimers disease and other dementia
6. Study: Adding Vimpat significantly reduces partial-onset seizures in adults with epilepsy
7. New study: Short coverage lapses limit childrens access to health care services
8. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
9. UNC study: Access to state childrens health insurance programs vital to disabled children
10. UNC study: Postmenopausal womens loss of sexual desire affects health, quality of life
11. Penn study: Breast cancer survivors call for more survivorship care from primary care physicians
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study: Genetic Risk for Substance Use Can be Neutralized by Good Parenting 
Study: Genetic Risk for Substance Use Can be Neutralized by Good Parenting
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10